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ABSTRACT
INVOLVEMENT OF PLATELET-DERIVED GROWTH FACTOR, PDGF RECEPTOR 
SIGNALING, FOCAL ADHESION KINASE AND SRC IN PRESSURE-INDUCED 
VASCULAR SMOOTH MUSCLE HYPERTROPHY
Darian Clark Rice, MID.
Old Dominion University and Eastern Virginia Medical School
August 2002 
Director. Russell L. Prewitt, PhD
Elevated blood pressure is associated with varying degrees o f arterial remodeling. 
The mechanisms by which extracellular mechanical stress is converted into intracellular 
alterations in signal transduction and gene expression have yet to be fully elucidated. 
Our goal was to investigate the early events in the vascular smooth muscle response to 
acute hypertension and to identify mediators involved in long-term hypertensive 
remodeling.
In the acute phase o f hypertension we targeted cell surface integrin and growth 
factor receptors thought to be mechanically sensitive. The signaling molecules FAK, Src 
and ERK-MAPK are known to be triggered by integrin engagement and growth factor 
receptor tyrosine kinase (RTK) activation. Pairs of rat mesenteric arteries were 
pressurized to 90 mmHg (control), and then one was raised to 140 mmHg for I, 3, 5 or 10 
minutes. Western blotting using phosphorylation-specific antibodies revealed that Src- 
pY418 (autophosphorylation site) was elevated 3-fold over control values at 1 minute, 
whereas significant FAK-Y397 (autophosphorylation site) activation was observed only 
following 3 minutes of pressure stimulus, and was blocked entirely by PP1, a selective 
Src inhibitor. Src-pY215 activity, which is associated with prior activation of the PDGF
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receptor, was not apparent at any of the time points tested. In addition, peak ERK- 
MAPK activation was identified at 5 minutes and was not affected by the presence of AG 
1296, a PDGF receptor inhibitor. These data demonstrate that autophosphorylation of 
Src-Y418 is an early event in pressure mechanotransduction and is required for 
downstream FAK-Y397 activation, and PDGF receptor activation does not appear to be 
involved in the initial response.
With regard to chronic arterial remodeling, previous studies in our laboratory 
showed that PDGF-A mRNA expression is increased in IK. 1C hypertensive rats. We 
evaluated the ability of PDGF-AA to stimulate growth o f carotid vascular smooth muscle 
in normotensive rats. Results identified an outward hypertrophic growth response in a 
manner similar to that seen in hypertensive remodeling. Next we evaluated the effect of 
PDGF receptor inhibition on vascular hypertrophy and ECM modification in 1K1C 
hypertensive rats treated with CGP-53716, a PDGF receptor inhibitor. Our results 
indicated that PDGF receptor inhibition does not block the hypertensive hypertrophic 
response, although we found significant changes in extracellular matrix composition. 
Overall, it appears that PDGF is not an absolute requirement for hypertrophic remodeling 
in 1KIC hypertension, but may play a pivotal role in ECM modification.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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1CHAPTER I 
INTRODUCTION
Systemic hypertension is known throughout the medical community as the “silent 
killer”. Hypertension affects approximately 50 million individuals in the United States 
alone. Essential hypertension accounts for 95% of these cases, and yet the etiology 
remains a mystery. Regardless o f etiology, the resulting systemic manifestations have 
devastating consequences. The tremendous morbidity and mortality reflects the 
cardiovascular, cerebrovascular, and renovascular complications commonly associated 
with hypertension. Therefore, it is of great importance to gain insight into the molecular 
pathophysiological mechanisms which govern this process in order to develop more 
specific treatment strategies.
The pathologic changes associated with a chronic elevation in blood pressure 
include varying degrees of vascular smooth muscle hypertrophy and structural 
remodeling.1' 1 Initially, this may be a “normal” cellular response in order to remain 
intact in the face o f elevated pressure, but the long-term consequences of these changes 
actually perpetuate the hypertensive state. The mechanism(s) by which extracellular 
mechanical stress is converted into intracellular alterations in signal transduction and 
gene expression have yet to be fully elucidated. The increased pressure load produces 
increased circumferential wall stress that is somehow translated, or “mechanically 
transduced”, into a message that triggers cellular growth and remodeling. The regulation 
of such a complex process seems to be multi-factorial in nature, and appears to be
The format o f this dissertation is based on the journal, Hypertension.
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initiated at the cell surface and modulated through interactions between multiple 
intracellular signaling pathways.
Cells detect and transmit sensory data from their environment in a variety of 
ways. In the case o f hypertension, cell surface receptors or associated molecules may be 
the sensors that perceive changes in extracellular pressure, and act as molecular switches 
to regulate vascular adaptation. Current evidence suggests that integrins (extracellular 
matrix receptors) and/or growth factor receptors may function as cell surface mechanical 
sensors. Therefore, we targeted the intracellular signaling molecules Src, Focal Adhesion 
Kinase (FAK), and ERK-MAPK (Extracellular Signal-Regulated Kinase of the Mitogen- 
Activated Protein Kinase family), which are associated with integrin receptors, focal 
adhesion sites, and growth factor receptor tyrosine kinases (RTK). O f the known RTKs, 
preliminary data gathered in our laboratory directed us to specifically explore the role of 
Platelet-derived Growth Factor and its receptor in both acute and chronic arterial 
remodeling.




Flow (Q) is directly proportional to the pressure gradient (AP) and is inversely 
related to resistance (R) as represented by the equation Q = AP/R. Blood pressure (AP) 
can therefore be defined as the product o f cardiac output (Q) and systemic vascular 
resistance (R). Intravascular pressure is very tightly regulated via feedback mechanisms 
to ensure proper perfusion of all bodily tissues. Any alteration in these mechanisms 
which leads to an increase in cardiac output or systemic vascular resistance without 
compensation may lead to hypertension. In reality, what is seen in the vast majority of 
chronic systemic hypertensive subjects is elevated vascular resistance (via reduction of 
vessel lumen diameter) at the level o f the small arterioles. Poiseuille helped us to 
understand that the principal determinant o f vascular resistance is vessel radius. He 
expanded the flow equation to account for the contribution of vessel length (L), radius (r), 
and fluid viscosity (r|), Q = jr(AP)rV8qL. Rearranging this formula to examine the 
physical components of hydraulic resistance yields R = AP/Q = 8qL/xr4.3 The fact that 
vascular resistance is inversely proportional to the fourth power o f the radius 
demonstrates that even small reductions in lumen diameter can cause significant 
elevations in blood pressure.
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4Vascular Mechanical Forces
As blood pulses through arteries it imparts various mechanical forces on the 
vascular wall. Theses forces include fluid shear stress, which is the axial frictional drag 
force produced by blood moving across the endothelial surface, and transmural 
circumferential wall stress, which is the radial force which causes deformations in the 
elastic vessel wall in response to the moving pressure head. Such forces have a 
significant influence on vascular biology and are believed to play a key role in both the 
acute regulation of arterial tone and chronic structural remodeling.4
Circumferential wall stress (WS), or “hoop stress”, is the force exerted 
perpendicular to the axis o f flow and is related to transmural pressure (P), vessel radius 
(r), and wall thickness (WT), by the Law of LaPlace which states that WS = Pr/WT. Our 
focus has been on the vascular smooth muscle cells, which are located beneath the 
endothelium and are generally shielded from the direct shear forces of flowing blood. 
Therefore, we hypothesize that transmural wall stress may be the key hemodynamic 
factor which directs the cellular response to increases in intravascular pressure. In 
hypertension, arterial vessels thicken their wall via hypertrophy and/or structurally reduce 
lumen radius, thereby reducing wall stress, which provides compelling evidence that wall 
stress is in fact the governing force behind vascular remodeling. In addition, work in our 
laboratory has demonstrated that various cellular growth regulatory mechanisms correlate 
with wall stress in pressure-stimulated isolated resistance vessels.5’6
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Vascular Remodeling in Hypertension
Chronic hypertension is associated with increased peripheral resistance to blood 
flow.7 As mentioned previously, this phenomenon can be attributed to a structural 
reduction in lumen diameter at the level of the small arteries and arterioles. These 
"resistance vessels" are vessels with a relaxed diameter o f <400 pm7 and possess an 
intrinsic ability to develop myogenic tone.8 This ability to generate spontaneous tone 
allows arterioles to vasoconstrict in order to regulate distal flow and counteract an 
increase in wall stress due to elevated pressure.9, 10 Over time, the sustained 
vasoconstriction will prompt a more permanent structural reduction in lumen diameter 
through inward eutrophic remodeling, in which VSMCs within the media reorganize 
around a smaller lumen.11 This phenomenon has been demonstrated in both the non­
renin-dependent 1 -kidney-1 -clip and renin-dependent 2-kidney-1-clip experimental 
models of chronic hypertension.12,13 Interestingly, once this remodeling has occurred, 
vascular tone is returned to normal. Some smaller arterioles will even close completely 
(i.e. functional rarefaction), which may then lead to structural rarefaction in which the 
vessels atrophy entirely.14 The larger arteries, or "conducting vessels", lack myogenic 
tone and eventually undergo outward hypertrophy in order to "tolerate" or counteract the 
increase in wall stress. The medium sized arteries located at the transition point between 
the conduit and resistance circulation demonstrate intermediate qualities and undergo 
both inward and outward hypertrophy (see Figure l) .15
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Figure 1. Vascular adaptations associated with the development o f hypertension.
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7Anatomy of the Vascnlar Wall
In order to appreciate the significance of potential interactions between various 
components within the vessel wall, it is important to briefly review vascular anatomy. 
The arterial wall can be broken down into three major concentric layers. The innermost 
layer is the tunica intima, which consists o f a single layer of endothelial cells overlying a 
thin basement membrane. The subendothelial compartment o f the intima is comprised of 
collagen fibers and vascular smooth muscle cells (VSMCs). The tunica media is the 
thickest of the three layers and is composed primarily of smooth muscle cell layers 
housed within a three-dimensional matrix. In chronic hypertension, these VSMCs may 
hypertrophy thus increasing wall thickness and/or reorganize thereby reducing lumen 
diameter. The outermost layer is the tunica adventitia which largely contains collagen 
fibers, fibroblasts, adipocytes and nerve endings.
The Vascular Extracellular Matrix
The vascular extracellular matrix (ECM) is a dynamic system of fibroelastic 
connective tissue organized into a functional lattice. The principle components of the 
complex three-dimensional network are collagen fibers (types I, HI, IV, V), 
proteoglycans, elastin, fibronectin, vitronectin, osteopontin, tenascin-C, laminin, and 
proteolytic enzymes (metalloproteinases) involved in the degradation and remodeling of 
the extracellular matrix. Within the vessel wall the smooth muscle cells are the major 
source of ECM protein production.16 Cross-links formed between these various 
components provide a mechanically-resistant scaffold, in which cells are anchored and 
guided during migration and reorganization. Many o f the components o f the ECM are
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
8connected to proteins o f the cytoskeleton by transmembrane proteins. At the cell surface, 
ECM receptors and cell adhesion molecules create an intercellular communication 
network that transmits critical information regarding the current state o f ceil adhesion, 
movement, and strain.17' 19 Such interactions provide key sensory information which 
regulates cell growth, differentiation, and migration. Matrix components such as 
proteoglycans (i.e. heparin-sulfate, etc.) may even assist with autocrine and paracrine 
functions of growth factors by serving as reservoirs and by regulating receptor 
interactions.20 Grako et al found that the transmembrane chondroitin sulfate 
proteoglycan, NG2, is required for Platelet-Derived Growth Factor Receptor alpha 
(PDGFRa) autophosphorylation and subsequent ellular events in aortic smooth muscle 
cells.21
Integrin Receptors
All cells contain membrane-anchored attachment proteins able to recognize 
specific motifs in the extracellular matrix and thus form a cellular scaffold. These cell- 
matrix interactions are primarily mediated by the integrin family o f cell surface ECM 
adhesion receptors. Integrin interaction with ECM components provides a certain 
cellular spatial awareness and an ability to sense and react to changes in cell adhesion, 
stability, strain, shear stress, as well as respond to a variety of other cellular stressors. In 
vitro experimental models using fibroblasts in a collagen gel have demonstrated that cells 
are in mechanical equilibrium with their supporting matrix, and that this interaction is 
integrin-dependent, and regulates their growth and determines their biosynthetic 
phenotype.22
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
9Integrins exist in a dynamic state of flux as heterodimers o f a  and P glycoprotein 
subunits which associate with ECM proteins such as collagen, fibronectin, laminin, 
osteopontin, fibrinogen, thrombospondin and vitronectin. 2 3  Twenty-two heterodimers 
formed from combinations of 17 types of a-subunits and 8  types of P-sub units have been 
identified thus far and differ with regard to substrate specificity. The predominance of 
aiPi, CZ3 P1, asPi, avpi and avP3 integrins in vascular smooth muscle cells (VSMC) suggests 
significant dependence on fibronectin, collagen, and laminin. 2 4  In hypertension, Bezie et 
al have found increased total fibronectin and asPi integrin in arterial vessels of 
spontaneously hypertensive (SHR) rats. 2 5  In addition, VSMCs exposed to mechanical 
strain demonstrated a 48% increase in fibronectin and a 50% increase in collagen. 2 6  
Mercurious et al found that when the fibronectin-integrin interface was disrupted with the 
recombinant fibronectin fragment, protein HI l-C, VSMC proliferation was reduced by 
75-90%.27 Overall, these data provide substantial evidence that integrin interaction with 
ECM constituents plays a key role in the regulation of cellular growth. Therefore, we 
hypothesize that these growth responses may be exaggerated in VSMCs exposed to a 
pressure stimulus.
Integrin engagement by ECM constituents completes a bridge linking the 
extracellular matrix to an intracytoplasmic domain containing both cytoskeletal and 
catalytic signaling components. Upon recognition of the extracellular ligand, activated 
integrins cluster to form focal adhesion sites and initiate the polymerization o f actin stress 
fibers. Engagement of the Pi integrin subunit by fibronectin recruits actin, vinculin, talin, 
and a-actinin which direct the assembly of actin stress fibers via a rho-dependent 
mechanism to help the cell adapt to changes in shape, adhesion and mechanical stress.-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Interestingly, Davies et al found that focal adhesions formed in endothelial cells exposed 
to shear stress in the form o f unidirectional laminar flow actually realign themselves 
along the axis o f flow, thereby reducing cellular tension.29
In addition to the formation of actin stress fibers, integrins transmit critical growth 
regulatory signals. Integrins do not intrinsically possess kinase activity, but upon 
activation recruit the assembly of several adaptor molecules and cytosolic protein 
kinases. Integrin engagement thereby initiates an intracellular phosphorylation cascade 
which transmits critical information regarding the state o f adhesion, migration and strain. 
The cell utilizes such data to direct growth, migration, proliferation, spreading, and to 
ultimately determine cell survival (see Figure 2).17’18' 3(K33
Focal Adhesion Kinase
Focal adhesion kinase (FAK) appears to be a central player in integrin signaling. 
FAK has been shown to associate not only with integrins and focal adhesion complexes, 
but also cell-to-cell cadherins/pecams, and growth factor receptor tyrosine kinases. FAK 
is a cytosolic protein tyrosine kinase (PTK), which upon activation, i.e. phosphorylation, 
has been shown to provide a substrate for association and activation o f other cytosolic 
proteins such as Src, phosphatidylinositol 3-kinase (PI3K), Grb2, paxillin, and pHO^15. 
Six FAK tyrosine phosphorylation sites have been identified (Y397, Y407, Y576, Y577, Y861, 
and Y925), which allow for the specific recruitment o f these proteins. Tyrosine residue 
397 (Y397) is the major site o f FAK autophosphorylation and serves as a docking site for 
the SH2/SH3 (Src homology 2/3) domain of Src34 and PI3K. PhosphatidyIinositoI-3 
kinase (PI3K) recruited by pY397 serves as an important regulator o f protein kinase B















N T E G R I N
MEK C E L L  
S U R V I V A L
MAPK
PI 3-Kinase
Figure 2. Diagrammatic representation of the involvement o f integrins in cellular growth 
and survival, (courtesy o f Calbiochem)
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(PKB, or Akt) and C (PKC), which act to inhibit apoptosis and promote cellular 
growth.35* 36 pY407 and pY861 appear to promote further SH2 domain binding, although 
their roles remain unclear. pY925 has been shown to attract Grb2, an adaptor protein 
which initiates the Erk 1/2 MAPK cascade.37"43
The Src Family of Protein Tyrosine Kinases
Src is another family of cytosolic non-receptor protein tyrosine kinases (PTK) 
which are involved in various signal transduction pathways associated with vital 
processes such as cell growth, adhesion, and differentiation. Src is a 60 kD protein 
comprised o f six distinct functional domains: SHI (Src Homology I) is the catalytic 
kinase domain; SH2, SH3, and a unique domain regulate interactions with target 
substrates, SH4 ts a reversible membrane binding region, and the C-terminal region 
which plays a significant role in the regulation o f Src kinase activity. Like other 
tyrosine kinases, Src catalyzes the transfer o f phosphate from ATP to tyrosine residues on 
target proteins. Src kinase activity is tightly regulated via two major phosphorylation 
sites. Phosphorylation of Src tyrosine 416 (Y416) within the catalytic site of the SHI 
domain enables full activation of the kinase. Src-Y527 is located in the C-terminal region 
and is the site of negative regulation, which when phosphorylated, renders the Src 
molecule inactive. C-terminal Src kinase (Csk) acts to maintain Y-527 phosphorylation 
in the absence o f substrate binding. Intramolecular interactions between the SH2 domain 
and the C-terminal phosphotyrosine 527 fold and stabilize the Src molecule in a closed 
inactive conformation. However, binding of protein targets in the SH2 or SH3 region, or 
loss of Y527 phosphorylation, disrupts the closed conformation and makes tyrosine 416
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
accessible for phosphorylation.44 Aside from substrate binding, Src-Y416 may also be 
activated via autophosphorylation induced by such triggers as mechanical stress45 despite 
inhibition by Src-pY527. Src-pY416 may then further act by dephosphorylating Src-Y527 to 
allow full activation of the Src molecule (see Figure 3).34’ 37' 44, 46*51 An additional 
phosphorylation site, Src-Y215, has been identified which correlates with Src activation 
following recruitment by an activated PDGF receptor.52
Src is intimately involved in the propagation o f various intracellular signaling 
cascades. Once recruited and/or activated, Src continues the phosphoregulatory cascade 
by association with various target proteins, kinases, and adapter molecules displaying 
SH2/SH3 domains. Known protein targets o f Src include the pi integrin; the integrin- 
dependent signaling molecules FAK, rho, paxillin, talin, vinculin, and tensin; PI-3 kinase; 
PLCy; and She and Ras, which are associated the Mitogen-Activated Protein Kinase 
(MAPK) growth regulatory signaling cascade.44 In hypertension, work in our laboratory 
has recently shown that Src is required for ERK-MAPK activation and c-fos induction in 
pressure-stimulated resistance arteries.53
The Mitogen-Activated Protein Kinases
The Mitogen-Activated Protein Kinases (MAPK) are a highly conserved family of 
serine/threonine kinases that are key regulators o f cellular growth. MAPKs appear to be 
activated by integrin engagement, cell stressors (mechanical strain, heat shock, osmotic, 
oxidative), and growth factor receptor activation (ex. PDGF-R, EGF-R, ATI). Three 
major subfamilies of MAPKs have been identified and include ERKs (Extracellular 
Signal-regulated Kinases), JNKs/SAPKs (c-Jun N-terminal Kinases or Stress-activated
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
14
Figure 3. A. A computer-generated image o f the three-dimensional structure of Src. B. 
An illustration of the regulation of Src kinase activity controlled primarily by Y416 and 
Y327 phosphorylation, (reproduced with permission from Schlessinger. J.. J Biol Chem 
1998)47
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Protein Kinases), and p38 MAPKs. These MAPKs are believed to play a critical role in 
the regulation o f cellular events such as cell growth, differentiation, and apoptosis. 5 4 ’ 5 5
ERK is activated primarily by growth factor receptor tyrosine kinase (RTK) 
stimulation, integrin engagement, or by angiotensin II (AH) binding to the AT-1 receptor. 
Autophosphorylation o f specific tyrosine residues in the activated RTK or stimulation of 
the G-protein coupled AT-l (Gq) receptor have been shown to recruit Grb2, an adaptor 
molecule, which appears to be the switch that activates the MAPK pathway. 
Subsequently, Grb2 forms a complex with Sos, a nucleotide exchange factor, and then 
converts Ras to its active GTP-bound form. The newly phosphorylated Ras then 
activates Raf-l, a serine/threonine kinase, which stimulates MAPK kinase (MEK) to 
phosphorylate ERK. Activated Erk 1/2 subsequently translocates to the nucleus where it 
stimulates ternary complex factors (TCF) such as Elk-1 to bind serum response factor 
(SRF). The TCF-SRF complex then binds the serum response element (SRE) located 
within the promoter o f proto-oncogenes such as c-fos, c-jun, and c-myc. The newly 
synthesized Fos and Jun proteins then dimerize to form the AP-I transcription factor 
which modulates the expression of target genes during various stages of the cell cycle 
(see Figures 4 and 5) . 5 5 -6 1  To prevent overexpression, feedback regulatory mechanisms 
such as MAPK phosphatase-1 (MKP-1) have been identified which are upregulated and 
inactivate MAPKs after stimulation by mitogens or cellular stress. 6 2
Erk 1/2 has also been implicated in the activation o f  p90 S6  kinase.63’ 6 4  The 
ribosomal protein S6  is thought to be one o f the key regulators o f protein synthesis. 
Phosphorylation o f S6  by p70 S6  kinase or p90 S6  kinase is correlated with an activation 
of protein synthesis at the level of initiation. The upstream components responsible for









Figure 4. Diagrammatic representation of the Erk-MAPKinase pathway in response 
to mitogen stimulation. (Courtesy of Sigma-Aldrich)
Figure 5. Transcriptional regulation by activated Erk-MAPK. (Courtesy of Sigma- 
Aldrich)
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p70 S6  kinase activation include growth factor or ATI receptor induced Erk 1/2 and PI- 
3K.
Implications for Collaborative Signaling in Hypertensive Hypertrophic Remodeling
With regard to hypertension, Li et. al. have recently demonstrated that cyclic 
stretch of aortic smooth muscle cells induces ERK 1/2, JNK, and p38, as well as MAPK 
phosphatase-1. 6 2 * 6 5  MacKenna et al have suggested that mechanical stress may stimulate 
ERK through the action o f c-Src, which is associated with focal adhesion kinase (FAK) at 
focal adhesion sites. 6 6  Sieg et al and others found growth factor receptors such as EGF- 
R, PDGF-R and AH-ATI receptors colocalized within focal adhesion sites67"69. 
Miyamoto et al further demonstrated that integrin occupancy by ECM ligands triggers not 
only integrin clustering but also induces the aggregation o f PDGF (platelet-derived 
growth factor), EGF (epidermal growth factor), and bFGF (basic fibroblast growth factor) 
receptors at the sites o f integrin clustering. ' 0  Interestingly, both PDGF and EGF induce 
focal adhesion formation via activation of members of the ras family o f GTP-binding 
proteins. 71 Interactions between integrins and ECM components have also been shown to 
regulate growth factor availability and receptor binding. Jones et al have demonstrated 
that interactions between avp3 integrins and tenascin-C to promote epidermal growth 
factor (EGF)-dependent growth in VSMCs. 7 2 In addition, Grako et al have shown that 
PDGFRa autophosphorylation is inhibited in aortic VSMCs lacking the ECM 
transmembrane proteoglycan, chondroitin sulfate NG2. 2 1 These findings suggest the 
possibility that integrins and growth factor receptors may collaborate in pressure-induced 
VSMC hypertrophy.
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But which o f these growth factors is responsible for pressure-stimulated growth in 
intact vessels? In an attempt to identify the mediators of pressure-induced hypertrophy, 
Parker et al in our laboratory investigated the role o f AH via the ATI receptor. In l- 
kidney-l-clip (1K1C) hypertensive rats, she demonstrated that ATI inhibition with 
losartan fails to inhibit the VSMC hypertrophy. 7 3 Berk et al reported that All-mediated 
hypertrophy o f vascular smooth muscle cells requires the presence o f PDGF-AA. 7 4  
Interestingly, Dobrian et al showed that PDGF-A, but not PDGF-B, mRNA expression is 
upregulated in IK 1C non-renin dependent hypertensive rats, and that the expression 
directly correlated with blood pressure. ' 5  In spontaneously hypertensive rats (SHR), 
Kitami et al have shown that increased PDGF-AA production directly contributes to the 
hypertrophy o f vascular smooth muscle cells (VSMC), and also found increased mRNA 
expression o f the PDGF alpha receptor (PDGFRa) . 7 6  Data gathered by Mulvany et al 
(data not published) has shown that ERK 1/2 is maximally activated at 5 minutes by 
PDGF, All, and pressure, an effect that is completely abolished by the PDGF receptor 
inhibitor, RPR 101115A. Interestingly, Hu et al demonstrated that the PDGFRa in 
VSMCs is activated by mechanical stress even in the absence o f ligand. 7 7  These data 
provide compelling evidence that the PDGF receptor may be the key element in pressure- 
induced hypertrophic signaling. Therefore, the role of PDGF and its receptor has become 
the target o f our current investigation.
Platelet-Derived Growth Factor and Its Receptor
Platelet-Derived Growth Factor (PDGF) is a polypeptide that was originally 
described by Ross et al. in 1974 as a platelet-dependent serum factor that potently
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stimulates cell proliferation and migration in vascular smooth muscle cells78. Since then, 
others have extended the spectrum o f PDGF expression to include all cells of 
mesodermal origin including endothelial cells, smooth muscle cells, fibroblasts, and 
placenta. 7 9
In vivo, PDGF exists as a disulfide-linked dimer o f A and B polypeptide chains 
which combine to form the three isomers PDGF-AA (26.5 kDa), PDGF-AB (25.5 kDa), 
and PDGF-BB (25.0 kDa). The A chain (PDGF-A) occurs in two versions as a result o f 
alternative splicing. The longer isoform (PDGF-AL) possesses a highly basic carboxy- 
terminal extension that is responsible for retaining PDGF-AL homodimers at the cell 
surface after secretion, while homodimers of the shorter isoform (PDGF-AS) are freely 
released into the extracellular space. Thus, PDGF dimers that contain PDGF-AL may 
assist in autocrine action by virtue of binding to heparin-like constituents o f the ECM. In 
fact, Fukuda et al have shown that the long-form o f PDGF A-chain contributes to the 
exaggerated growth of VSMC from SHR. 8 0
Once formed, the PDGF-AA, -AB, and -BB dimers differ in their cellular 
growth-promoting effects depending upon the receptor and cell type stimulated. The 
PDGF receptors belong to a family of cell surface growth factor receptor tyrosine kinases 
(RTKs) which are formed by the dimerization of a  and/or P receptor subunits to yield 
a a ,  ap , and PP receptor subtypes. In vascular smooth muscle cells, PDGF appears to 
regulate protein synthesis and cell growth via these receptors in an autocrine and 
paracrine manner. 81 In addition, Sjolund found that inhibition of extracellular PDGF 
binding by suramin did not prevent autocrine stimulation of DNA synthesis. This 
suggests that newly synthesized PDGF may have the ability to activate its receptor
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intracellularly and that autocrine action does not require release into the pericellular
82space.
The PDGF receptors demonstrate differential binding affinity for the three PDGF 
isoforms. The aa-receptor has been shown to bind all three isoforms, whereas the aP- 
receptor will preferentially bind PDGF-AB and PDGF-BB, and the PP-receptor displays 
an affinity only for PDGF-BB. Activation o f these PDGF receptors by ligand binding or 
another mechanism initiates a cascade o f growth regulatory signals. The key event in the 
activation of the PDGF receptor is the dimerization o f the two cytoplasmic tails that 
juxtapose various tyrosine residues and allow for trans-phosphorylation of the internal 
receptor components. The function of autophosphorylation is to regulate the catalytic 
activity of the receptor kinase and provide docking sites for downstream signal 
transduction molecules. The tyrosine autophosphorylation sites recognize binding 
domains such as Src homology 2 and 3 (SH2/SH3), phosphotyrosine binding (PTB) 
domains, and pleckstin homology (PH) domains. Several SH2-containing signaling 
molecules have been identified and include the Src family o f tyrosine kinases, FAX, 
phosphadidylinositol 3-kinase (PI-3K), phospholipase C-y (PLC-y), the tyrosine 
phosphatase SHP-2, and the GTPase activating protein for Ras (GAP). Adapter 
molecules such as Grb283, She, Nek, Grb7, and Crk are also recruited. Further 
downstream, these molecules propagate the signal by phosphorylating other targets such 
as protein kinase C (PKC), phospholipase D (PLD), Akt, S6  kinase, and the signal 
tranducers and activators of transcription (STATS) to promote cellular growth, 
proliferation and survival. 8 4 * 8 5
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In vascular smooth muscle cells (VSMC), Inui et al and others found that 
signaling mechanisms via PDGF-a and *P receptors distinctly differ in downstream signal 
transduction events. PDGF-BB is the most potent mitogen and stimulates DNA 
synthesis, actin filament rearrangement, anti-apoptotic mechanisms, and regulates 
calcium availability. 8 6 - 8 8  Stimulation by PDGF-AA primarily induces cellular 
hypertrophy (protein synthesis), but not hyperplasia, and also has a greatly diminished 
ability to regulate intracellular calcium. 8 4 , 8 6 , 8 7 , 8 9 - 9 2  These effects were further determined 
to result from differential activation of critical signaling molecules. The mitogenic action 
of PDGF-BB seems to be under the control o f PLD-dependent formation of phosphatidic 
acid (PA), whereas PDGF-AA does not cause an increase in PA production. Thus, PA 
may be a significant second messenger in the activation o f DNA synthesis by PDGF- 
BB. 8 7  In addition, Salhany et al have shown that PDGF-stimulated modulation o f gene 
expression occurs at least in part by induction of the immediate-early c-fos gene and by 
activation of the serum response element (SRE) . 9 3  Interestingly, Allen et al have detected 
significant c-fos expression in pressure-stimulated isolated vessels5, which is consistent 
with PDGF receptor-mediated signaling events.
Hypertension and ECM Modification
Extracellular matrix (ECM) modifications in the vascular wall may also 
contribute to arterial remodeling in hypertension. The current thought is that 
Transforming Growth Factor Beta (TGF-|3) and PDGF primarily govern the production 
o f ECM components. Halloran et al found that TGF-beta I regulates type I procollagen 
expression in adult human arterial SMC in part by inducing PDGF-A as a co-factor. 9 4
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Pressure or mechanical stress has also been shown to stimulate the synthesis of 
extracellular matrix (ECM) components such as collagen I & m , hyaluronate, and 
chondroitin-6 -sulfate. 9 5  Satoh et al have suggested that enhanced expression of TGF- 
betal, PDGF A-chain, AH, and bFGF may contribute to the exaggerated growth and 
remodeling of VSMC from SHR. 9 6  Bezie et al found increased cell-matrix attachment 
sites and total fibronectin in SHRs as compared to normotensive Wistar rats which 
suggests a role for both cellular and matrix components in vascular mechanical 
adaptation. 2 5  Therefore, in addition to promoting growth in vascular smooth muscle 
cells, PDGF may also coordinate ECM component production 9 7  and contribute to arterial 
remodeling in response to hypertension.
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CHAPTER m  
HYPOTHESES
I. The first hypothesis is that the PDGF receptor is activated by a pressure 
stimulus, even in the absence of ligand.
II. The second hypothesis is that Focal Adhesion Kinase, which is associated with 
integrin receptors and focal adhesion complexes, may initiate the hypertrophic 
response by autophosphorylation at Y-397.
HI. The third hypothesis is that the Src family of cytosolic tyrosine kinases facilitates 
the activation of Focal Adhesion Kinase and/or the PDGF receptor.
IV. The fourth hypothesis is that Platelet-derived Growth Factor AA directly 
stimulates hypertrophy in vascular smooth muscle cells and regulates extracellular 
matrix production.




The overall objective o f this research was to identify the mechanism(s) by which 
increased pressure stimulates hypertrophy in the vessel wall, specifically, the 
involvement of platelet-derived growth factor, its receptor signaling, and the early events 
in the vascular response to hypertension. The specific aims were to:
1. Identify the molecular pressure sensor(s) that initiates or facilitates the 
phosphoregulatory cascade leading to VSMC hypertrophy. Candidates that were 
investigated include the Src family of cytosolic protein kinases, Focal Adhesion 
Kinase (FAK), the Extracellular Signal-regulated Kinase subtype of the Mitogen 
Activated Protein Kinase (ERK-MAPK) family o f intracellular messengers, and 
PDGF receptor activation in response to pressure stimulus in isolated resistance 
arteries.
2. Determine the role of Platelet Derived Growth Factor AA isoform (PDGF-AA) in 
the initiation o f vascular smooth muscle hypertrophy, by direct infusion onto the 
carotid artery in normotensive rats.
3. Determine the influence o f Platelet Derived Growth Factor Receptor blockade in 
the hypertrophic response to hypertension, by utilizing the PDGF-R antagonist, 
CGP-53716, in 1K1C rat model o f chronic hypertension in rats. For acute studies.
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isolated vessels were pretreated with AG1296, a specific inhibitor of the PDGF 
receptor, pressurized and then analyzed for downstream ERK 1/2 activation.




All experimental procedures were approved by the institutional Animal Care and 
Use Committee.
Isolated Dual Vessel Protocol
Male wistar rats (200-410 g) were anaesthetized with pentobarbital (60 mg/kg IP). 
After midline laparotomy and perforation of the heart, the mesenteric arcade was 
carefully dissected away from the associated length of intestine, and placed in cold (4° C) 
bicarbonate-free physiological saline solution (PSS), with the following composition (in 
mmol/L): NaCl 141.8, KC1 4.69, MgSCL 1.59, EDTA 0.513, CaCl2 2.79, HEPES 10.0, 
KH2 PO4  1.18, and glucose 5.0, adjusted to a pH of 7.37-7.4. First order mesenteric small 
arteries were then cleared free of surrounding adipose tissue and mounted in a dual vessel 
chamber (Living Systems Instrumentation, Burlington, VT, USA, model CH/2/M). 
Isolated arteries were cannulated onto tapered glass micro-pipettes (outside diameter 210 
- 250 pm) with the aid of a dissection microscope, and were secured using 19 pm nylon 
filament. Once the vessels were mounted, the chamber was transferred to the stage of an 
upright microscope (Zeiss), where the transilluminated vessels could be visualized on 
CCTV. The internal and external diameters were measured and recorded with the aid of 
video calipers (Texas A&M). The intraluminal pressure was controlled by adjusting the 
height o f a fluid reservoir, and was recorded continuously via pressure transducers. The 
pressure in both vessels was gradually raised in a step-wise fashion (15 mmHg every 15
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minutes) to a normal mean arterial pressure of 90 mmHg, at 37° C. Following a 1-hour 
equilibration at 90 mmHg, one o f the vessels was raised to a hypertensive pressure of 140 
mmHg for 1, 3, or 5 minutes, while the other remained at 90 mmHg to serve as the 
experimental control.
In order to reduce variability, all experiments were performed in a paired fashion, 
and both arteries were isolated from the same rat. For experiments evaluating the role of 
Src in pressure mechanotransduction, PP1 (10 pM). a specific inhibitor of Src that does 
not interfere with FAK autophosphorylation 98, was administered extraluminally in the 
tissue bath during the I-hour equilibration period. AG 1296, a specific inhibitor of the 
PDGF receptor, was administered in the same fashion.
Tissue Homogenation Protocol
At the endpoint o f each experiment, both vessels were removed from the cannula, 
immediately snap frozen in liquid nitrogen, and then ground in 50 pL of cold 
radioimmunoprecipitation (RIP A) protein extraction buffer o f the following composition: 
Tris 50 mmol/L, NaCI 150 mmoI/L, 1% NP-40, 0.25% Na-deoxycholate, and EDTA I 
mmol/L. In addition, the buffer also contained the protease inhibitors, Aprotinin I 
pg/mL, Leupeptin I pg/mL, Pepstatin Ipg/mL, and Phenylmethylsulphonylflouride 
(PMSF) I mmol/L, and the phosphatase inhibitors, sodium orthovanadate (NajVCXi) 1 
mmol/L and sodium fluoride (NaF) 1 mmol/L. The tissue homogenate was then 
centrifuged at 11,000 rpm for 20 minutes and the supernatant transferred to an eppendorf 
tube. Samples were then stored at -70°C until further processing.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
28
Micro Bicinchoninic Acid (BCA) Protein Assay
The total protein content o f each vessel homogenate was determined using the 
Micro-BCA (bicinchoninic acid) protein assay (Pierce). For small protein samples, the 
Micro-BCA assay is a sensitive method for quantitative colorimetric determination of 
total protein content in dilute aqueous solutions (0.5-20 pg/ml).99
The Micro BCA Protein Reaction Scheme:
1. Protein (peptide bonds) + Cu2+-t- OH* -> tetradentate-Cu1* complex
2. Cul+ complex + BCA -> BCA-Cul+ complex (purple colored)
3. Read absorbance at 562 nm
A standard curve was first generated by preparing serial dilutions of a BSA stock 
standard (2 mg/ml). The protocol required I ml of each standard dilution or 5 pi of 
protein sample + 995 pi dHiO to be placed in a clear cuvette. One ml of working reagent 
(25 parts Micro BCA reagent A, 24 parts reagent B, and I part reagent C) was added to 
each standard and sample. The tubes were then incubated for 60 minutes at 60°C. Once 
cooled to room temperature, the absorbance was measured at 562 nm vs. a water 
reference. Using the standard curve, the protein concentration of each unknown sample 
was determined.
Sodium Dodecyl Sulfate -  Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Protein samples were standardized and prepared with dithiothreitol (DTT) and 
Laemmli buffer (10% SDS, 0.3125 M Tris, 50% glycerol, 25% P-mercaptoethanol, 0.5%
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bromophenol blue). Equal amounts o f protein were then loaded and separated by 
electrophoresis (45 minutes at 180-200 V) using a 7.5-12% SDS-polyacrylamide gel. A 
prestained rainbow markers (Amersham Pharmacia Biotech) was used as a molecular 
weight standard.
Western Blotting
Following SDS-PAGE, the gel was equilibrated in transfer buffer (25 mM Tris, 
192 mM glycine, 20% MeOH) prior to transferring the protein to PVDF membranes (100 
V x 60 min or 110 V x 75 min). The membrane was blocked in a 1:1 solution of non­
animal protein NAP-Sure Blocker (Geno Technology) and Tris-buffered saline with 1% 
Tween-20 (T-TBS) for I hour at room temperature (RT). Membranes were incubated 
with a polyclonal phosphorylation-specific 1° antibody for 1-2 hours at RT, followed by 
alkaline phosphatase conjugated goat anti-rabbit secondary antibody (Tropix) for I hour. 
Membranes were then washed in T-TBS followed by Assay buffer (20 mM Tris, 1 mM 
MgCh, 0.1 M diethanolamine, pH 9.8-10.0) prior to incubation with the developing 
reagent (CDP-Star, Tropix). The enhanced chemiluminescent (ECL) signal was detected 
by Kodak Digital Imaging System, and the band signal intensity was quantified using 
SigmaGel digital software.
Western Reprobe Protocol
The membrane was first washed in T-TBS for 5 min, placed in a 50 ml Falcon 
tube, and then “stripped” of bound antibodies using Reprobe solution (16 ml dHiO +- 4 
ml 5x Reprobe solution) for 20 minutes. After stripping, the membrane was washed in T-
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TBS 3 x 5  minutes and then in Assay buffer 2 x 2  minutes. The blot was then drained 
and covered with 3 ml Tropix Developing Reagent (CDP-Star) for 5 minutes at room 
temperature. The membrane was then allowed to develop for 30 minutes and then 
imaged using Kodak Digital Imaging software (to confirm successful stripping). The 
membrane was then ready for incubation with 1° antibody.
1-Kidney, 1-Clip (1K1C) Surgical Procedure
Anesthetized (ketamine-HCl 80 mg/kg and xylazine 12 mg/kg, or pentobarbital 
60 mg/kg IP) male Wistar rats (200-350 g) were placed in anatomic position on a sterile 
drape. Following the induction of surgical anesthesia, a midline abdominal incision was 
made and the left renal vascular bundle exposed by blunt dissection. The renal artery and 
vein were carefully separated to isolate the renal artery and to allow careful placement of 
the silver Goldblatt clip (230 pm gap). The kidney was then monitored for adequate 
renal perfusion. Once the left renal artery was stabilized, the right renal artery was 
exposed for the placement of two ties around the artery-vein bundle. The right kidney 
was then removed by clipping between ties and then bluntly dissecting the surrounding 
connective tissue kidney capsule. The muscular abdominal wall was closed using 
interrupted or running 4-0 Vicryl sutures. The skin incision was then closed by skin 
stapling or placement of several interrupted stitches using 5-0 nylon sutures. As a 
precautionary measure, penicillin G 25,000 U EM was also given.
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Surgical Placement of Carotid Catheter and Mini-osmopump
Anesthetized (pentobarbital 60 mg/kg IP) male Wistar rats were placed on a 
sterile drape-covered cork board in anatomic position. Hypothermia was prevented by 
placing the surgical board on a heating pad. Surgery was performed with the aid o f a 
dissection microscope, using sterile technique. A midline incision (1-1.5 cm) was first 
placed in the anterior neck. The right common carotid artery was exposed by careful 
blunt dissection between the trachea and sternocleidomastoid muscle. Micro-retractors 
were used to aid in the exposure. Once the right carotid artery was carefully freed of 
surrounding vessels and nervous tissue, a specially designed catheter (microrenathane 
tubing perforated at the site o f anticipated saline or PDGF-AA delivery) was placed 
parallel and adjacent to the carotid. The catheter was then secured by placing a cuff 
around both the catheter and carotid, and by directly suturing to nearby musculature.100 
Once secure, the distal end of the catheter was tunneled subcutaneously around the base 
of the lateral right neck and between the scapulae where the catheter was attached to a 
mini-osmopump (Alzet Model 2002, Alza Corp, Palo Alto, CA) with a pumping rate of 
0.5 p. 1/hr x 14 days. The connection between the catheter and minipump was reinforced 
with a suture to prevent disconnection during the course of the experiment. All incisions 
were closed with surgical staples or interrupted stitches.
Paraffin Tissue Embedding and Slide Preparation Protocol
Tissues harvested for staining or immunohistochemistry were first placed in 
labeled tissue paper, and allowed to bathe in 10% phosphate-buffered formalin for a 
period of 4 hours. The tissues were then processed through graded ethanol solutions in
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an automated tissue processor (Technicon) overnight. Once processed, tissues were 
vertically oriented in plastic tissue trays and embedded in hot paraffin wax. Once cooled, 
tissues were ready for microtome sectioning and slide preparation.
Immunohistochemistry for PDGF-AA
Slides of paraffin embedded tissue were placed in a slide carrier and warmed in an 
oven at 55°C for I hour. Slides were then deparaffinized and rehydrated by washing in 
xylene ( 3 x 5  minutes), then 100% EtOH (3 x 10 minutes), followed by 95% EtOH (2 x 
10 minutes), and finally in 70% EtOH (I x 10 minutes). The slides were then rinsed in 
distilled H2O for 5 minutes. Next, the slides were incubated with 0.3% H2O2  in cold 
methanol (200 ml MeOH + 6 ml H2O2 ) for 30 minutes in order to block the endogenous 
peroxidase and permeabilize the tissue. The slides were then washed in PBS (for 2 x 5  
minutes) prior to preincubation with 5% normal goat IgG (NGS) in PBS/0.1%BSA (30 
minutes) to block nonspecific binding. The next step involved incubation with the 1° 
antibody (dilution 1:100 in PBS/NGS/0.i%BSA) in a humidification chamber for 2 hours 
at room temperature (or 4°C overnight). The slides were then washed in PBS ( 3 x 5  
minutes) and PBS/0.1%BSA (15 minutes) prior to incubation with the biotinylated 2° 
antibody (goat anti-rabbit IgG) (dilution 1:500 in PBS/0.1%BSA) for 30 minutes. Next, 
the slides were washed in PBS ( 3 x 5  minutes) and PBS/0.1% BSA (15 minutes), prior to 
incubation with Vectastain for 30 minutes. Slides were then washed in PBS for 10 
minutes and then rinsed in 1% TritonX-100/PBS for 30 seconds. Once allowed to air 
dry, the slides were incubated with 0.1% diaminobenzene (DAB) Metal/Stable Peroxide 
Buffer for 5-15 minutes slides in a humidification chamber, until brown staining was
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visible. The slides were then washed under cold running tap water for 5 minutes, and 
then counterstained with hematoxylin for 3 minutes. The slides were once again washed 
under cold tap water for 5 minutes. Dehydration and clearing involved washing the 
slides in 70% EtOH (2 x 10 minutes), followed by 95% EtOH (2 x 10 minutes), then 
100% EtOH (2 x 10 minutes), and finally xylene (2 x 10 minutes). After the final step, 
slides were allowed to air dry prior to applying a coverslip. The slides were then ready 
for microscopic evaluation.
Immunocytochemistry for BrdU
Incorporation of bromo-deoxyuridine (BrdU) in the nuclei was used as a marker 
of DNA replication during the infusion period. Sections o f paraffin-embedded tissues 
were deparaffinized, rehydrated, and blocked for endogenous peroxidases. DNA was 
denatured by treatment with 2N HC1 for 30 minutes at 37°C, enzymatically pretreated 
with trypsin, and then incubated with 5% normal goat serum (NGS). Tissues were then 
incubated with mouse monoclonal anti-BrdU, while negative control sections were 
incubated in 5% NGS. All tissues were then incubated with biotinylated secondary 
antibody IgG, stained with Vectastain Elite avidin-biotin complex kit, and incubated with 
0.1% diaminobenzene (DAB) in Stable Peroxide Buffer. Kidneys from each animal were 
also evaluated for the incorporation of BrdU as a positive control.
Totuidine Blue Staining
Thin sections (5 pm) o f paraffin-embedded tissue were stained with toluidine blue 
to assist in the visualization o f the vascular intima and media. Slides were first
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deparaffinized in xylene (3 minutes x 2), then rehydrated in 100% EtOH (10 dips x 3), 
95% EtOH (10 dips x 1), and then dHzO (5 minutes). Slides were then placed on a 
warmer at 37°C and stained with toluidine blue dye for I minute. Excess dye was rinsed 
off with dHjO prior to dehydration using 95% EtOH (10 dips), 100% EtOH (10 dips), 
and xylene (3 minutes x 2).
Pico-Sirius Red Staining
Thin sections (5 pm) of paraffin-embedded tissue were stained with Pico-Sirius 
Red to allow the quantification o f total collagen in the vascular wall using NIH digital 
imaging software. Slides were first deparaffinized in xylene (5 minutes x 3), then 
rehydrated in 100% EtOH (1 min x 2), 95% EtOH (I min), 70% EtOH (I min) and then 
dHzO (I min). Slides were then stained with Pico-Sirius Red dye for I hour, followed by 
2 washes in 30% acetic acid and dehydration using 70% EtOH (20 dips), 95% EtOH (20 
dips), 100% EtOH (20 dips), and xylene (20 dips x 3).
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated by first homogenizing tissues in guanidine isothiocyanate 
(GITC) and (3-mercaptoethano 1 (BME). The RNA was further separated from DNA and 
proteins by cold ethanol precipitation followed by total RNA recovery using a GlassMax 
RNA Micro-isolation Spin Cartridge System (GIBCO). The total RNA was reverse 
transcribed by incubating the sample at 42°C for 30 minutes in the presence of 
Oligo(dT)i5  primer, AMV reverse transcriptase, dNTPs, MgCh and ribonuclease 
inhibitor (Promega Reverse Transcription System, Cat. # A3500). The reaction mixture
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was heated to 95°C for 5 minutes and then rapidly cooled to 4°C to inactivate the reverse 
transcriptase and prevent it from binding to the newly formed cDNA. The cDNA was 
then amplified using Fa^BEAD Hot Start Polymerase (Promega, Cat.# M5661), dNTPs, 
MgCl2  and primer pairs for either Collagen I, Collagen LH, or PDGF-A. Cyclophilin was 
used as the reference housekeeping gene. The following rat sequences were used as 
primers: I) COL 1: 5’-TGCCGTGACCTCAAGATGTG-3\ 5’-CACAAGCGTGCT- 
GTAGGTGA-3 2) COL LH: 5’-AGATCATGTCTTCACTCAAGTC-3\ 5’-TTTAC- 
ATTGCCATTGGCCTGA-3’; 3) PDGF-A: 5’-AAGCATGTGCCGGAGAAGCG-35’- 
TCCTCTAACCTCACCTGGAC-3’; and 4) Cyclophilin: 5’-GTCGCGTCTGCTTCGA- 
GCTGTTTGC-3’, 5’-CCATGGCTTCCACAATGCTCATGCC-3’.101 ‘ 102 All primers 
were purchased from GIBCO BRL. Preliminary experiments were performed to establish 
the linearity range and optimal annealing temperatures for each PCR reaction. In all 
cases, the cDNAs were heated at 94°C for 30 s, annealed for another 30 s, and subjected 
to a 72°C extension for I min. The PCR reaction for Collagen I and HI was performed at 
an annealing temperature o f 60°C for 36 cycles. RNA was also amplified using the 
PDGF-A primers for 35 cycles at an annealing temperature o f 58°C. The reaction for 
cyclophilin was performed under the same conditions as for the respective target genes. 
The PCR products were electrophoresed on a 1% agarose gel and stained with ethidium 
bromide. The band signal intensity was measured by densitometry using an EagleEye 
System (Stratagene) and quantitated using SigmaGel software (Jandel Scientific). 
GraphPad Instat software was utilized for statistical analysis of experimental means, 
standard error, and analyses of variance. Results are expressed as the ratio (mean + 
SEM) of target mRNA vs. cyclophilin housekeeping control mRNA.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
36
CHAPTER VI 
THE ROLE OF INTEGRIN AND PDGF RECEPTOR SIGNALING IN 
THE EARLY VSMC RESPONSE TO PRESSURE STIMULUS
Introduction
To briefly summarize, wall stress is believed to be the major determinant 
underlying the development o f vascular hypertrophy in hypertension. Current literature 
supports the theory that increased wall stress is "sensed" (via mechanotransduction 
mechanisms) by the vascular smooth muscle cells (VSMC) which then initiates an 
integrated intracellular signaling pathway leading to iong-term cellular modification. 
Evidence is accumulating that this process may be coordinated through cellular 
attachments between the ECM and the cytoskeleton and/or via mechanically sensitive 
transmembrane growth factor receptors. Integrins sense changes in the extracellular 
environment by direct attachment to components in the ECM and neighboring cells. 
FAK associates with integrins, focal adhesion complexes, and growth factor receptor 
tyrosine kinases. Upon phosphorylation, FAK provides a substrate for association with 
and activation of other cytosolic proteins, including Src. FAK-Y397 is the major site of 
FAK autophosphorylation and serves as docking site for the Src homology (SH2/SH3) 
domain o f Src.34 Therefore, FAK is a potential candidate for initiation o f the 
phosphoregulatory cascade. However, Src originating from other activated receptors may 
have the ability to migrate and stimulate pathways via SH2/SH3 binding domains, 
including FAK37’103 and RTKs. Src-Y418 is a major site of autophosphorylation, and Src-
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Y215 can be phosphorylated by the PDGF receptor.52 Therefore, the question to be 
answered is whether FAK, Src, ERK 1/2, or PDGF-R autophosphorylation is the 
initiating event, or is it a collaborative effort?
Methods
In order to delineate the intracellular signaling pathway in the initial phase of 
acute hypertension, pairs of rat mesenteric arteries were cannulated onto tapered glass 
pipettes in a dual-vessel chamber. Once secured, the vessels were pressurized in a 
stepwise fashion (15 mmHg every 15 min) to a mean arterial pressure o f 90 mmHg. The 
vessels were allowed to equilibrate at 90 mmHg for one hour, at which point one was 
raised to 140 mmHg for I, 3, 5, or 10 minutes. The vessel remaining at 90 mmHg was 
used to serve as an experimental normotensive control. Immediately following the 
experiment, both vessels were snap-frozen in liquid nitrogen and then homogenized in 
RIPA buffer containing protease and phosphatase inhibitors. Western blotting was 
performed on these samples to determine the presence o f activated FAK, Src, and ERK 
1/2 by using phosphorylation-specific antibodies to FAK-pY397, Src-pY2ts, Src-pY418, 
and p-ERK 1/2. Once this information was gathered, inhibitors were employed to further 
delineate the sequence of involvement.
Of the Src tyrosine kinase inhibitors (PP1, PP2, and herbimycin) tested in our lab, 
PPl appeared to be the most potent and was used in the following experiments.104 
Tyrphostin AG 1296 is a highly selective PDGF receptor kinase inhibitor that has little 
effect on the EGF-R, FGF-R, VEGF-R, or Src kinase activity and was also utilized.105’ 
106.107 inhibitors are not yet available.
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Wesselman et al in our laboratory recently showed that Src inhibition attenuates 
ERK 1/2 activation and c-fos induction in pressurized isolated vessels.53 Therefore, we 
utilized PP1 (10 pM) to identify changes in FAK-Y397 phosphorylation in the absence of 
Src activation. We also confirmed the efficacy o f PPl by evaluating its effect on Src- 
Y418 phosphorylation. Finally, we used AG 1296 (10 pM) to examine the effect of PDGF 
receptor inhibition on downstream ERK 1/2 activation.
Results
Ninety-three pairs o f rat first-order mesenteric arteries were utilized in this study. 
During the isolated vessel experiments, the arteries responded to the incremental 
increases in pressure in a passive manner. Each 15 mmHg pressure increase resulted in a 
corresponding increase in lumen diameter and circumferential wall stress. Use of the Src 
tyrosine kinase inhibitor, PPl (10 pM), or the PDGFR inhibitor, AG 1296 (10 pM), did 
not appear to influence these vessel characteristics. Occasionally, pressures o f 90 mmHg 
or 140 mmHg triggered a moderate myogenic response. As wall stress is believed to be 
the key determinant in the vascular growth response to hypertension, and myogenic tone 
has been shown to attenuate the pressure-induced c-fos expression, these vessels were not 
included in the study.6
The following results are presented as mean ±  SEM. GraphPad Instat software 
was used for determination o f mean and SEM, followed by paired t-test for statistical 
significance. The null hypothesis was rejected at P<0.05, and n depicts the number of 
paired experiments.
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In order to determine the involvement o f focal adhesion kinase, Src, and ERK 1/2 
in the initial events of pressure mechanotransduction, we examined the temporal 
phosphorylation patterns o f these cellular components within the first 10 minutes of acute 
hypertension. Western blotting with a phosphorylation-specific primary antibody to 
FAJC-pY397 was performed on 21 pairs of vessels subjected to pressure stimulus for I, 3, 
or 5 minutes. As shown in Figure 6, one minute at 140 mmHg revealed no significant 
change (P>0.05, n=6) in FAK-Y397 activation as compared to experimental control 
vessels at 90 mmHg. However, 3 minutes at 140 mmHg increased FAK-pY397 1.9 + 0.24 
fold over control (PO.Ol, n=6), and by 5 minutes was elevated 2.54 + 0.33 fold over the 
90 mmHg control (P<0.001, n=9). These results show that FAX tyrosine residue 397 is 
not immediately autophosphorylated by high pressure, but becomes significantly 
activated by 3 and 5 minutes of pressure stimulus.
To further unravel cellular events during the acute phase of hypertension, we 
investigated the effect of pressure on Src-Y215 and Src-Y418 phosphorylation. Western 
blotting using a primary antibody to Src-pY215 was performed on vessel homogenates 
from a total of 25 paired experiments. The results indicate that activation of Src-Y215 is 
not involved in the first I, 3, or 5 minutes o f pressure challenge (see Figure 7). However, 
Src-pY418 appears to be a key player in the initial events. Western blotting with a 
phosphorylation-specific primary antibody to Src-pY418 was utilized to evaluate pressure- 
induced activation at 1,3, and 5 minutes. Results based on the analysis o f 15 vessel pairs 
indicate a substantial 2.54 + 0.16 fold increase (P<0.001, n=5) in Src-Y418 
phosphorylation at 1 minute, 2.86 + 0.22 fold increase (P0.001, n=5) at 3 minutes, and 
a return to baseline (P>0.05, n=5) following 5 minutes o f pressure stimulus. These
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results clearly demonstrate a significant involvement of Src-pY418 in the initial cellular 
response to acute hypertension.
With regard to ERK 1/2, Wesselman et al in our laboratory has previously 
demonstrated consistent Erk 1/2 phosphorylation following 5 minutes o f pressure 
stimulus.53 As an additional measure, we wanted to duplicate these results in our system. 
Western blotting using a phosphorylation-state specific antibody to p-ERK 1/2 was used 
to analyze vessel homogenates o f experiments conducted at 1,5, and 10 minutes o f acute 
hypertension. At one minute o f pressure stimulus no significant change in ERK 1/2 
activation was apparent (P>0.05, n=5), whereas by 5 minutes p-ERK 1/2 levels were 
significantly elevated by 3.22 + 1 .0  fold over baseline values (P<0.01, n=7). However, 
by 10 minutes, ERK 1/2 phosphorylation had returned to baseline values (P>0.05, n=5) 
(see Figure 8). The ERK-MAPKs are clearly involved in pressure-mechanotransduction, 
but their activation occurs later in the signaling sequence than Src and FAK.
Src-pY418 is significantly activated by I minute at 140 mmHg, and is followed by 
FAK-Y397 phosphorylation at 3 and 5 minutes. To determine if FAK-Y397 activation is 
Src-dependent, 9 additional paired experiments were performed on PPt treated vessels. 
PP1 was selected for these experiments for its superior ability to inhibit Src activity based 
on previous work in our laboratory which compared the efficacy o f Herbimycin A, PPl, 
and PP2 in similar vessel experiments.53 Western blotting using the primary anti-FAK- 
pY397 antibody revealed that PPl completely blocked FAK-Y397 activation at 1,3, and 5 
minutes of pressure stimulus (see Figure 6). These results demonstrate the requirement 
o f Src tyrosine kinases in the downstream pressure-induced activation of FAK-Y397.
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Our next step was to evaluate the influence of PDGF receptor inhibition on 
pressure-mediated signaling events. Based on our previous finding that Src-Y215 is not 
activated within the first 5 minutes o f pressure stimulus, and that Src is required for 
downstream ERK 1/2 activation, we felt that the PDGF receptor may not be activated 
directly by pressure, but instead may be a target of Src-pY418. In that way, signaling 
pathways may be operating in parallel to collaborate in mechanotransduction. We 
considered the possibility that integrin and PDGF receptor signaling pathways may 
converge in downstream activation of ERK 1/2. Since we have demonstrated that ERK 
1/2 activation peaks at 5 minutes of pressure stimulus, we examined the effect o f PDGF 
receptor inhibition on ERK 1/2 phosphorylation at 5 minutes of pressure challenge. 
However, results indicate that PDGF receptor inhibition does not attenuate downstream 
ERK 1/2 activation, and that levels of p-ERK 1/2 in the presence or absence of AG 1296 
remained consistently elevated at 5 minutes of 2.76 + 0.32 vs. 3.22 ±  1.00 fold over 
baseline, respectively (P>0.05, n=7) (see Figure 8). However, the possibility remains that 
the PDGF receptor may be involved at a latter stage of the pressure-mediated growth 
response.
Discussion
Our long-term goal has been to characterize the pressure-induced hypertrophic 
growth response in vascular smooth muscle. The ERK-MAPKinase pathway has been 
linked to the cellular growth response. Activated ERK 1/2 has been shown to translocate 
to the nucleus where it stimulates ternary complex factors (TCF) to bind serum response 
factor (SRF). The TCF-SRF complex then binds to the serum response element (SRE)
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within the promoter of immediate early proto-oncogenes such as c-fos, c-jun, and c-myc. 
The newly synthesized fos protein has been shown to then dimerize with jun to form the 
AP-l transcription factor, which modulates the expression o f key growth regulatory
55-57.60.61genes.
ERK 1/2 appears to be activated by growth factor receptor tyrosine kinases 
(RTK), integrin receptor engagement, angiotensin AT-1 receptor stimulation, and 
mechanical strain. Hu et al. have demonstrated ERK1/2 activation following 
autophosphorylation o f RTKs in response to cell stretch, in the absence of growth 
factors.77 Li et al. have recently shown that cyclic stretch o f aortic smooth muscle cells 
induces ERK 1/2, JNK, and p38, as well as MAPK phosphatase-1.62,65 Mechanical stress 
may also stimulate ERKl/2 through the action of c-Src, which is associated with focal 
adhesion kinase (FAK) at focal adhesion sites.66 Wesselman et al. demonstrated that 
ERK 1/2 activity peaks at 5 minutes of pressure stimulus in isolated small mesenteric 
arteries and subsequently gives rise to an increased expression o f the immediate early 
gene, c-fos. Src inhibition using PPl, PP2, or Herbimycin A not only blocked c-fos 
expression, but also inhibited ERKl/2 activation.53 Collectively, work in our laboratory 
has shown that Src tyrosine kinases mediate pressure-induced ERK-MAP Kinase 
activation and c-fos expression, and that this response is correlated to wall stress.3,6,53,58
The next step in our investigation was to target events upstream of ERK 1/2 
activation in an effort to identify the initial cellular trigger o f the pressure-induced 
signaling cascade. Cellular components at or near the plasma membrane were the targets 
of this investigation. Integrins seemed like an ideal candidate due to their ability to sense 
and react to changes in cell adhesion, shear stress, and mechanical strain, through direct
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interaction with the extracellular matrix. Src and FAK are key components of integrin 
signaling, and are also involved in growth factor receptor tyrosine kinase pathways. In 
the present study, we demonstrate that acute hypertension triggers immediate Src-Y418 
autophosphorylation in intact isolated resistance arteries, and is required for downstream 
activation of FAK-Y397. The involvement of FAK reinforces the growing body of 
evidence that suggests the potential collaboration among integrins and growth factor 
receptor tyrosine kinases in the pressure response.70
Hu et al. demonstrated that mechanical strain can activate the PDGF-Ra in the 
absence of ligand.77 Interestingly, EGF and PDGF receptors are colocalized within focal 
adhesion sites.67, 68 Stover et al. recently showed that activation o f the PDGF receptor 
triggers phosphorylation o f Src at tyrosine residue 215.52 In the present study we probed 
for the presence o f Src-pY215 in pressurized vessels and our findings demonstrated an 
absence o f Src-pY215 activity at any time point investigated. This suggests that prior 
PDGF receptor phosphorylation is not necessary for Src activation. Furthermore, we 
have found that selective PDGF receptor inhibition with AG 1296 failed to blunt ERK 
1/2 activation at 5 minutes o f pressure challenge. However, a few possibilities remain:
I) that PDGF receptor signaling converges at a point downstream o f ERK 1/2, or 2) the 
PDGFR may not actually be mechanically sensitive, but is instead a target of activated 
Src, FAK, or even ERK 1/2.108 Mechanical strain has been shown to increase the 
expression of PDGF-AA and its receptor, and therefore suggests that the acute signaling 
pathway may initiate a more long-term response through the increased production and 
autocrine action o f PDGF.76
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Overall, the current study provides evidence that Src-pY418 may be the messenger 
that initiates the cascade and propagates the signal to other key players such as FAK. 
The results of these experiments are incorporated into Figure 9 that depicts a theoretical 
signaling mechanism by which hypertension stimulates cellular growth in vascular 
smooth muscle cells. The remaining question is what activates Src? The mechanism by 
which Src, a cytosolic component, becomes activated remains unclear, although reactive 
oxygen species (ROS) have recently been implicated.46 Reactive oxygen species and 
growth factors stimulate similar intracellular signal transduction events including 
activation of Src kinase family members and extracellular signal-regulated kinases 
(ERKl/2). A potentially important downstream effector o f Src and ERKl/2 is p90 
ribosomal S6 kinase (p90RSK), which plays an important role in cell growth by 
activating several transcription factors. Abe et al found that Fyn (Src family member) was 
essential for H2O1  stimulated ERKl/2 and p90RSK activity, suggesting a redox-sensitive 
mechanism of Ras and p90RSK regulation.109 In addition, H^Ch-activated Src has been 
shown to transactivate growth factor receptors such as the epidermal growth factor 
receptor (EGF-R), which may amplify the signaling cascade.110 Therefore, pressure- 
stimulated production of ROS may be the initial trigger activating Src which in turn 
phosphorylates and activates FAK, the PDGF receptor, and other members of the 
mechanotransduction cascade. However, a mechanism by which mechanical strain 
causes immediate oxidative stress has yet to be identified. Another possibility is that Src 
itself is mechanically sensitive. In an isolated tendon preparation, Banes et al have 
demonstrated that cyclic mechanical loading induces rapid Src phosphorylation within 5 
seconds, and reaches a plateau within 30 seconds. They hypothesized that Src is part of a











Figure 9. Diagrammatic representation of the theoretical mechanism by 
which hypertension stimulates vascular smooth muscle hypertrophy. Our findings 
suggest that increased wall stress triggers the activation of c-Src. which then 
becomes associated with focal adhesion kinase (FAK) at focal adhesion sites. 
Downstream, the ERK-MAPK pathway mediates c-fos expression and 
subsequent upregulation of critical growth regulatory components. The PDGF 
receptor does not appear to involved in the acute phase of mechanotransduction. 
but may play a role in long-term vascular remodeling. The red circles indicate 
phosphorylation steps.
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mechanosensory complex linking integrins to the cytoskeleton, and attribute this response 
to perturbations in the cytoskeleton that may induce a conformational change in Src 
leading to enhanced kinase activity.111
In conclusion, we have shown that Src autophosphorylation is an early event in 
pressure-mediated signaling in isolated resistance vessels. In addition, we have shown 
that Src is required for downstream activation o f FAK and ERK 1/2, although the 
relationship between them remains unclear. The PDGF receptor does not appear to be 
involved within the first 5 minutes o f pressure stimulus, but may act further downstream 
and/or contribute to long-term vascular remodeling.
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CHAPTER VH
THE ROLE OF PDGF AND ITS RECEPTOR IN LONG-TERM
ARTERIAL REM ODELING
Introduction
In pressurized isolated resistance vessels we have shown that the “acute phase” of 
hypertension involves the initiation of an intracellular phosphoregulatory signaling 
cascade which utilizes Src, FAK, and ERK 1/2, and culminates in altered gene 
expression. We hypothesize that this acute phase sets the stage for transition into a 
chronic phase, during which time arterial remodeling is initiated and persists as long as 
the pressure or wall stress remains elevated.
The vascular changes associated with chronic hypertension include medial 
hypertrophy of the large conduit arteries which transitions towards inward eutrophic 
remodeling as vessels enter the resistance circulation. This response appears to be 
governed by changes in wall stress, where WS = Pr/WT. The large arteries increase their 
wall thickness (WT) and the small arterioles reduce their radius (r), both of which 
counteract increases in wall stress (WS). However, the mechanism by which wall stress 
triggers long-term arterial remodeling has yet to be fully elucidated.
Recent evidence has suggested that growth factors and/or their receptors may be 
mediators in the pathway towards smooth muscle hypertrophy within the vessel wall. 
Initially, angiotensin II acting via the ATI receptor was believed to regulate vascular 
growth and remodeling although evidence is accumulating that implicates Platelet
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Derived Growth Factor, specifically PDGF-AA. Wang et al previously demonstrated that 
remodeling of large and small arteries in angiotensin H-induced hypertensive rats was 
paralleled by an increased expression o f platelet-derived growth factor (PDGF)-A chain 
mRNA, but only in the hypertrophied large arteries.112 In non-renin-dependent l-kidney- 
1-clip (IK1C) hypertensive rats, Parker et al demonstrated that ATI inhibition with 
losartan fails to inhibit the VSMC hypertrophy.73 Dobrian et al later showed that PDGF- 
A, but not PDGF-B, mRNA expression is upregulated in 1K1C hypertensive rats, and 
that the expression directly correlated with blood pressure and wall area.75 Berk et al 
reported that All-mediated hypertrophy o f vascular smooth muscle cells requires the 
presence of PDGF-AA.74 In spontaneously hypertensive rats (SHR), Kitami et al have 
shown that increased PDGF-AA production directly contributes to the hypertrophy of 
vascular smooth muscle cells (VSMC), and also found increased mRNA expression of 
the PDGF alpha receptor (PDGFRa).76 Taken together, these data suggest a direct effect 
o f elevated pressure on PDGF-AA expression, which may be involved in the onset and 
progression of vascular hypertrophy.
The purpose of our current study was to evaluate the ability o f PDGF-AA to 
induce hypertrophy in large arteries of normotensive rats, and also to examine the effect 
of PDGF receptor inhibition on hypertensive remodeling and extracellular matrix 
production.
Methods
Phase 1 of the study involved local delivery of PDGF-AA to the perivascular 
space around the right carotid artery. Male Wistar rats (228-395 g) were randomly
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divided into three groups: PDGF-AA 24 ng/d (n = 6), PDGF-AA 48 ng/d (n = 5), or 
sterile saline-infused controls (n = 5). All rats were anesthetized using ketamine-HCl (80 
mg/kg IP) and xylazine (12 mg/kg), and given a prophylactic dose o f penicillin G (25,000 
U EM). Using sterile technique, the right carotid artery was carefully isolated and freed 
of surrounding tissue. The proximal end of a specially designed catheter (microrenathane 
tubing perforated at the site of saline or PDGF-AA delivery) was secured parallel and 
adjacent to the right carotid.100 Once secure, the distal end o f the catheter was tunneled 
subcutaneously around the base o f the lateral right neck and between the scapulae. The 
catheter was then flushed with PDGF-AA or sterile saline and attached to a mini- 
osmopump (Alzet Model 2002, Alza Corp, Palo Alto, CA) implanted between the 
scapulae. The pumps were filled with saline, PDGF-AA [2 ng/pl] or [4 ng/pl] to deliver 
the desired dosage at 0.5 |ii/hr x 14 days.
In order to distinguish hypertrophy from hyperplasia, all rats were given BrdU 
(5,-bromo-2’-deoxyuridine), which is readily incorporated into the DNA of replicating 
cells, in their drinking water (0.8 mg/mi) for the duration of the study.113 The animals 
were housed one per cage to ensure the consumption and enable the calculation of the 
dose o f dHiO/BrdU received
After 14 days, all rats were anesthetized (sodium pentobarbital 60 mg/kg IP) and 
both carotid arteries (the left was used as a self-control) and the remaining kidney (BrdU 
control) were harvested. The tissues were fixed in 10% phosphate-buffered formalin, 
dehydrated in a stepwise fashion through graded concentrations o f  ethanol, and then 
embedded in paraffin for immunohistochemistry and morphometric analysis. 
Immunohistochemistry was performed on paraffin-embedded carotid sections to
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determine the presence and distribution of PDGF-A chain. Tissues were first 
deparaffinized and rehydrated in graded ethanols. Endogenous peroxidase was blocked 
by incubation in 0.3% H2 O2  in cold methanol, and nonspecific binding was blocked by 
incubation with 5% normal goat serum (NGS) in PBS/0.1%BSA. The sections were then 
incubated with a polyclonal rabbit anti-human antibody (dilution 1:100 in 
PBS/NGS/0.1%BSA, overnight at 4°C in humidification chamber) that recognizes both 
human and rat PDGF-A chain.114 After successive washings in PBS and PBS/0.l%BSA, 
the slides were incubated with the biotinylated 2° goat anti-rabbit antibody (dilution 
1:500 in PBS/0.1%BSA for 30 min) (Vector Laboratories, Burlingame, CA). Next, the 
slides were washed prior to incubation with Vectastain Elite avidin-biotin complex kit, 
and then with 0.1% diaminobenzene (DAB) Metal/Stable Peroxide Buffer. Finally, the 
slides were counterstained with Gill’s hematoxylin, dehydrated and coverslipped.
Immunocytochemistry was also performed on paraffin-embedded sections to 
identify cells actively undergoing DNA synthesis via the incorporation of bromo- 
deoxyuridine (BrdU). Carotid and kidney sections were deparaffinized, rehydrated, and 
blocked for endogenous peroxidases. DNA was denatured and histones were dissociated 
by treatment with 2N HC1 for 30 minutes at 37°C, then enzymatically pretreated with 
trypsin, and blocked with 5% normal goat serum (NGS). Tissues were then incubated 
with either mouse monoclonal anti-BrdU (1:200) or 5% NGS (negative control sections). 
All tissues were rinsed and then incubated with biotinylated secondary antibody IgG 
(1:400), stained with Vectastain Elite avidin-biotin complex kit, and incubated with 0.1% 
diaminobenzene (DAB) in Stable Peroxide Buffer. Kidneys from each animal were 
evaluated for the incorporation o f BrdU as a positive control.
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In addition, thin sections (5 pm) of paraffin-embedded tissues were stained with 
toluidine blue for measurement of wall area and lumen diameter using the JAVA digital 
edge-tracking software. The mean of three measurements was used in the calculation of 
wall area and lumen diameter. The data was statistically interpreted using one-way 
analysis o f variance. Results are presented as mean + SEM and n = number of rats.
Phase 2 o f this study involved the characterization o f vascular remodeling in one- 
kidney-1-clip (IBCIC) hypertensive rats vs. uninephrectomized normotensive (IBCNC) 
controls in the absence o f PDGF receptor activation by using CGP 53716, a selective 
inhibitor of the PDGF receptor kinase.115 Male Wistar rats (163-210 g; Harlan Sprague 
Dawley, Indianapolis, IN) were randomly divided into four groups: IBCIC + CGP (n = 7), 
IK1C + vehicle (n = 8), IBCNC + CGP (n = 6), and IBCNC +■ vehicle (n = 5). All rats 
were anesthetized using ketamine-HCl (80 mg/kg IP) and xylazine (12 mg/kg), and given 
a prophylactic dose of penicillin G (25,000 U IM). The IK1C technique involved the 
placement of a silver clip (230 pm gap width) around the left renal artery followed by 
removal o f the right kidney.116 In the control rats the left renal artery was isolated in the 
same manner as in the 1BCIC technique although without clip placement, and was 
followed by right uninephrectomy. Beginning post-operative day 3, all rats received a 
daily IP injection o f either CGP 53716 (50 mg/kg IP; 10 mg/ml in 0.9% sterile saline, 5% 
DMSO, and 1% Tween 80)117' 118 or an equivalent dose of vehicle.
The onset and development of hypertension was tracked by measuring the systolic 
tail-cuff blood pressure using a Narco Biosystems Electro-Sphygmomanometer 
(Houston, TX). Measurements were taken on wanned conscious rats beginning the day 
prior to surgery and then every third day postoperatively (days 3, 7, 10, and 13) until
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completion of the study. The average of three pressure tracings was recorded for each 
measurement.
After 14 days, all rats were anesthetized (sodium pentobarbital 60 mg/kg IP) and 
then sacrificed by decapitation. The thoracic and abdominal aorta, femoral artery, and 
small mesenteric arteries were harvested and prepared for evaluation. One segment of 
each vessel was fixed in 10% phosphate-buffered formalin, dehydrated in a stepwise 
fashion through graded concentrations of ethanol, and then embedded in paraffin for 
histolologic and morphometric analysis, as previously described. Thin sections (5 pm) 
paraffin-embedded tissues were rehydrated through graded ethanols and either stained 
with toluidine blue for measurement o f wall area and lumen diameter using the JAVA 
digital edge-tracking software, or stained for collagen using Pico-Sirius Red and 
evaluated for collagen content using Scion (NIH) digital software. The mean of three 
measurements was used in the calculation of wall area, lumen diameter, and collagen 
content.
Another piece from each vessel was immediately homogenized in guanidine 
isothiocyanate and p-mercaptoethanol (BME) to liberate RNA from the tissue. This was 
then separated from DNA and proteins with a cold ethanol precipitation and total RNA 
recovered using a GlassMax RNA Micro-isolation Spin Cartridge System (GEBCO). 
Total RNA was then reverse transcribed using the Promega Reverse Transcription 
System (Cat. # A3500). The cDNA was then amplified using Taq&EAD Hot Start 
Polymerase (Promega, Cat.# M5661), dNTPs, MgCh and primer pairs for either Collagen 
I, Collagen HI, or PDGF-A. Cyclophilin was used as the reference housekeeping gene. 
The following rat sequences were used as primers: 1) COL I: 5’-
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TGCCGTGACCTCAAGATGTG-3 ’, 5 ’-CACAAGCGTGCT-GTAGGTGA-3 ’; 2) COL 
IE: 5 ’ - AG ATC ATGT CTTC ACT C AAGTC-3 ’, 5’-TTTACATTGCCATTGGCCTGA-3’;
3) PDGF-A: 5’-AAGCATGTGCCGGAGAAGCG-3\ 5’-TCCTCTAACCTCACCTG- 
GAC-3’; and 4) Cyciophilin: 5 ’-GTCGCGTCTGCTTCGA-GCTGTTTGC-3 \  5’- 
CCATGGCTTCCACAATGCTCATGCC-3’.101’102 In all cases, the cDNAs were heated 
at 94°C for 30 s, annealed for another 30 s, and subjected to a 72°C extension for I min. 
The PCR reaction for Collagen I and III was performed at an annealing temperature of 
60°C for 36 cycles. cDNA was also amplified using the PDGF-A primers for 35 cycles at 
an annealing temperature o f 58°C. The reaction for cyciophilin was performed under the 
same conditions as for the respective target genes. The PCR products were 
electrophoresed on a 1% agarose gel and stained with ethidium bromide. The band signal 
intensity was measured by densitometry using an EagleEye System (Stratagene) and 
quantitated using SigmaGel software (Jandel Scientific). Results are expressed as the 
ratio (mean + SEM) of target mRNA vs. cyciophilin housekeeping control mRNA.
Results
For the PDGF-AA perivascular infusion study, GraphPad Instat software was 
used to perform a one-way ANOVA to evaluate the effect o f PDGF-AA on vessel 
structure as compared to control groups. For the CGP-53716 study, Number Cruncher 
Statistical Systems (NCSS 2000) software was utilized to perform two-way analyses of 
variance in order to identify the combined and individual contribution of hypertension 
and drug treatment on measured outcome across all study populations. All results are 
presented as experimental means + standard error, and n = number o f  rats.
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Our goal was to evaluate the ability o f the PDGF-AA isofonn to stimulate 
hypertrophy in the smooth muscle cells within the carotid wall in vivo. We began by 
performing morphometric analyses on toluidine blue stained carotid sections using JAVA 
digital edge-tracking software. In normotensive rats that received a direct continuous 
perivascular infusion o f PDGF-AA for 14 days, cross-sectional wall area was 
significantly increased (P < 0.05) in the right PDGF-AA infused carotids as compared to 
both the left untreated carotid from the same animals and the saline treated experimental 
controls (see Figure 10). There was no significant difference between the 24 ng/d and the 
48 ng/d treatment groups (P > 0.5) suggesting that 24 ng/d was sufficient to elicit the 
maximal growth response. This increase was not accompanied by an enlargement o f the 
vessel lumen, calculated as internal diameter, which remained consistent across the study 
groups. Such findings are indicative of outward hypertrophy.
Our experimental design permitted the direct perivascular infusion o f PDGF-AA 
around the right carotid artery for 14 days. However, the ability o f PDGF to penetrate 
through the adventitia and into the media was uncertain. Therefore, in order to 
characterize the presence and distribution o f PDGF-AA within the carotid wall we 
performed immunohistochemistry on paraffin-embedded carotid cross-sections. The 
staining was unevenly distributed but significantly more pronounced in the wall of 
PDGF-AA treated vessels as compared to the left carotid (self control) and carotids of 
saline-infused animals. Staining was seen primarily in the media and subintimal layers. 
There was also an enhanced staining of the adventitial layer compared with control 
arteries. The same pattern of distribution was observed in all specimens examined, albeit 
the intensity o f the staining slightly varied with each section. The staining seemed to be
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Figure 10. Eflect o f Saline (NS) vs. PDGF-AA Infixsion on Carotid 
Wall Area and Lumen Diameter
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specific for PDGF-AA because the negative controls sections were consistently free of 
staining. The possibility that the PDGF-AA that was detected was endogenously 
produced was also considered, although sections from same-animal left carotid controls 
failed to stain in the same maimer (see Figure 11).
Thus far, we have shown that carotid arteries exposed to PDGF-AA in vivo 
exhibit outward hypertrophy, and confirmed that perivascular PDGF-AA delivery 
penetrates all layers of an intact vessel in our experimental system. However, we have 
yet to determine whether PDGF-AA triggers hypertrophy or hyperplasia in the vascular 
wall. To answer this question, we administered 5-Bromo-2-DeoxyUridine (BrdU) in the 
drinking water of all rats for the duration of the study. BrdU is a pyrimidine analog of 
thymidine which is selectively incorporated into cell DNA during the S phase of the cell 
cycle. Therefore, BrdU will identify cells that have undergone proliferation/hyperplasia 
and will not be incorporated into the DNA of hypertrophic cells. However, BrdU cannot 
distinguish hyperplasia from polyploidy. Immunocytochemistry was performed on 
paraffin-embedded carotid cross-sections using a mouse monoclonal anti-BrdU antibody 
(Sigma) and revealed no significant nuclear staining for BrdU within the vessel media in 
any o f the treatment groups. A few sparse endothelial or subintimal smooth muscle cells 
appeared to demonstrate specific staining, although this finding was inconsistent and may 
have been the result of polyploidy or antibody trapping at the luminal border. Adventitial 
fibroblasts from both saline and PDGF-AA treated carotids demonstrated consistent 
staining as well as the kidney positive control sections (see Figure 12).
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Figure 11. Immunohistochemistry using anti-PDGF-AA antibody. Images 
A.B.C.D represent the saline (NS) treated experimental group. A: Right carotid 
(NS delivered via implanted catheter): B: Right carotid (IHC control): C: Left 
carotid (non-treated self control): D: Left carotid (IHC control). Note the
absence of positive staining. Images E.F.G.H represent the PDGF-AA (24 ng'd) 
treated experimental group (R6). E: Right carotid (PDGF-AA delivered via 
implanted catheter): F: Right carotid (IHC control): G: Left carotid (non-treated 
self control): H: Left carotid (IHC control). Note the positive staining in slide E. 
Images LLKX represent the PDGF-AA (48 ng/d) treated experimental group 
(R12). I: Right carotid (PDGF-AA delivered via implanted catheter): J: Right 
carotid (IHC control): K.: Left carotid (non-treated self control): L: Left carotid 
(IHC control). Note the positive staining in slide I.
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Figure 12. Immunocytochemistry using anti-BrdU antibody. Images A. B. C. D 
represent the saline treated group. A: Right carotid (infused): B: Right carotid ICC 
control: C: Left carotid untreated self control: D: Left carotid ICC control. Images E. 
F. G. H represent the PDGF-AA (24 ng/d) group. E: Right carotid (infused): F: Right 
carotid ICC control: G: Left carotid untreated self control: H: Left carotid ICC control. 
Images I. J. K. L represent the PDGF-AA (48 ng/d) group. I: Right carotid (infused): J: 
Right carotid ICC control: K.: Left carotid untreated self control: L: Left carotid ICC 
control. Images M. N are kidney sections used as experimental controls. M: positive 
control: N: ICC control
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Systolic blood pressures as measured by the tail-cuff method were significantly 
elevated above control levels in IK1C rats starting postoperative day 4 and continued to 
rise until study completion on day 14. At day 4, measurements indicated a significant 
increase (P<0.001) in the IKIC rats (1K1C-CGP 143 + 3.6, and IK1C 142.5 + 
5.26 mmHg) as compared with control rats (IKNC-CGP 122.5 + 2.14 and 1KNC 122 +
3.00 mmHg). This trend continued throughout the duration o f the study and by day 14 
the IK1C-CGP rats reached 184.3 + 6.3 and LKIC rats were 188.8 + 5.57 whereas 
control rats remained near baseline pressures (IKNC-CGP 117.5 + 4.03 and IBCNC
115.0 + 4.18 mmHg) (see Figure 13). CGP-53716 had no apparent influence on the 
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Dobrian et al in our laboratory previously showed that PDGF-A mRNA is 
significantly upregulated in IK. 1C hypertensive rats, and we have also provided evidence 
that PDGF-AA stimulates outward hypertrophy in large arteries. The next step was to 
determine if PDGF receptor inhibition has any influence on arterial remodeling in 
hypertensive rats. In our IKIC hypertensive model, we found that CGP-53716 had little 
effect on pressure-induced hypertrophy in the thoracic aorta. Both the hypertensive 
groups demonstrated a significant increase in both wall area (P < 0.0001) and lumen 
diameter (P < 0.01) as compared to normotensive controls. Measurements taken from the 
femoral arteries (FA) o f these same rats showed a similar trend in wall area (P < 0.0001) 
and lumen diameter (P < 0.00001) in both IKIC groups over both normotensive controls.
In sections taken from the small mesenteric arteries (SMA) there was also a significant 
increase in wall area (P < 0.005), although lumen diameter remained constant (P > 0.05) 
across all study groups (see Figure 14). Overall, both large and small arteries from 
hypertensive rats demonstrated pressure-dependent outward hypertrophy, and treatment 
with CGP-53716 had no apparent effect on this response.
We further investigated the possibility that PDGF may contribute to arterial 
remodeling by regulating ECM collagen production. This was accomplished by 
measuring total collagen content in CGP-treated and non-treated normotensive and 
hypertensive rats. Thoracic and femoral cross-sections were stained with Pico-Sirius red 
to identify collagen in the vessel wall, and NIH Scion imaging software was used to 
calculate the percent collagen. The average o f four measurements per section was then 
multiplied by the wall area to yield total collagen content. In thoracic sections, there was 
no significant difference between IKIC and 1KNC untreated rats (P > 0.05), but there
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was a significant reduction in 1K1C CGP-treated rats as compared to 1K1C untreated (P 
< 0.001). We also found a significant overall reduction in collagen content in CGP- 
treated versus untreated rats. However, in femoral sections, we found no significant 
variation (P > 0.05) between any of the experimental groups (see Figure 15).
Since collagen I and HI are the most abundant components in the vascular ECM 
we also used RT-PCR to identify changes in their expression in response to pressure 
and/or PDGF receptor inhibition. Sections of thoracic aorta and femoral arteries from all 
study groups were analyzed. To standardize the measurements, collagen I and HI mRNA 
expression was compared to cyclophilin mRNA as the internal control, and the 
collagenrcyclophilin ratio was used for statistical analysis. Results indicated a significant 
reduction in collagen I (P < 0.05), but not HI (P > 0.05), mRNA expression in the 
thoracic aortas o f CGP-treated animals as compared to their untreated counterparts (see 
Figure 16). This finding parallels the reduction o f total collagen content seen in thoracic 
cross-sections. In the femoral artery, we found no significant (P > 0.05) change in 
collagen I or HI expression between any o f the experimental groups (see Figure 17), 
which also corresponds to the measured collagen content.
Discussion
The vascular changes associated with chronic hypertension include outward 
medial hypertrophy o f the large conduit arteries which transitions towards inward 
eutrophic remodeling as vessels enter the resistance circulation. However, the 
mechanism(s) which governs this vascular growth response has yet to be fuUy elucidated.
In SHRs, Negoro et al found increased PDGF-A expression in VSMCs and suggested that
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blood pressure modulates its expression to promote hypertrophy within the vessel wall.119 
Wang et al found enhanced expression of PDGF-A within the arterial wall o f All-induced 
hypertensive rats.112 Previous studies in our laboratory showed that PDGF-A, but not 
PDGF-B, mRNA expression is increased in 1KIC hypertensive rats, and that the 
expression is directly correlated to pressure. In addition, the study also revealed 
increased PDGF-AA protein localized primarily within the medial layers of the vessel 
wall. The fact that PDGF acts in an autocrine and paracrine manner, suggests a possible 
role in hypertensive remodeling.
The purpose of the first phase of our study was to further evaluate the ability o f 
PDGF-AA to directly stimulate growth within vascular smooth muscle in a large artery of 
normotensive rats. Results from the study identified a significant increase in the wall 
area o f PDGF-AA-treated carotids as compared to both saline-treated and same-animal 
controls, which provided evidence that PDGF-AA does indeed induce vascular smooth 
muscle growth in vivo. In addition, the lumen diameters of all study groups remained 
constant, which suggests that the infusion triggered outward growth. We further 
delineated the potential contribution of hyperplasia, polyploidy, and hypertrophy in this 
response by simultaneously treating all rats with BrdU, a thymidine analog. As 
evidenced by the lack o f positive BrdU incorporation in all experimental tissues, the 
growth response was consistent with hypertrophy. Overall, data from our study suggests 
that PDGF-AA triggers an outward hypertrophic growth response in a manner similar to 
that seen in hypertensive remodeling.
The next phase o f the study was designed to identify the effect of PDGF receptor 
inhibition on vascular hypertrophy and ECM modification in chronic hypertensive
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remodeling. Previous studies conducted by Fukuda et al found that treatment with the 
antisense oligodeoxynucleotide to PDGF-A mRNA inhibits the arterial growth in 
spontaneously hypertensive rats without altering their blood pressure.101 This finding 
provided further support o f our hypothesis linking the PDGF receptor to vascular 
remodeling. We performed similar studies in 1K1C hypertensive rats using CGP-53716, 
a highly selective inhibitor o f PDGF receptor protein tyrosine kinase activity. At the end 
o f the 14 day experimental period, we examined large and small arteries for changes in 
wall area, lumen diameter, total collagen content and collagen I and HI mRNA 
expression.
Our results indicate that PDGF receptor inhibition with CGP 53716 does not 
block the hypertensive hypertrophic response in the thoracic aorta, femoral arteries, or 
small mesenteric arteries. However, we found significant changes in extracellular matrix 
composition. In sections taken from the thoracic aorta, total collagen content was greatly 
reduced in the CGP-treated hypertensive rats as compared to the untreated IK. 1C group, 
although in femoral sections we found no significant change in total collagen between 
any of the experimental groups. These findings are consistent with our RT-PCR data 
which identified a similar trend in collagen I mRNA expression. Holloran et al provided 
further support by demonstrating that PDGF-AA is a requisite cofactor for the expression 
o f collagen I mRNA in VSMCs.94 In addition, Rice et al found that inhibition o f the 
PDGF receptor significantly reduced collagen synthesis in myofibroblasts.120 Therefore, 
differences in ECM production between the aorta and femoral arteries may reflect a 
different time course for ECM remodeling or may signify inherent variations in vessel 
structure. Overall, it appears that activation o f the PDGF receptor is not an absolute
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requirement for hypertrophic remodeling in IK1C hypertension, but may play a pivotal 
role in ECM modification.
Our findings are supported by a growing body o f evidence that suggests that 
vascular remodeling is a coordinated effort between several growth factors and their 
receptors. In VSMCs isolated from SHRs, Satoh et al found enhanced expression of 
PDGF-A-chain, transforming growth factor (TGF)-betal, and basic fibroblast growth 
factor (bFGF) mRNAs as compared to cells from normotensive Wistar Kyoto rats, and 
suggested that these growth factors collaborate in the growth response.96 Itoh et al 
demonstrated that AH induces VSMC hypertrophy via upregulation o f PDGF-AA. TGF- 
P, and bFGF.121 Iwasaki et al reported that mechanical stress triggers ERK 1/2 activation 
and can stimulate growth in VSMCs via the epidermal growth factor receptor (EGF-R), 
and does not require activation of the PDGF receptor.122 These data suggest the 
involvement of other receptors that may be operating in parallel or become upregulated in 
the absence of PDGF receptor signaling.
Recently, the potential role of oxidative stress in hypertensive vascular 
remodeling has also been emphasized. Production o f reactive oxygen species (ROS), 
normally generated as byproducts of enzymatic processes in cellular metabolism, may 
accelerate under pathologic conditions thus leading to oxidative stress. Bae et al have 
shown that signaling through the PDGF receptor can trigger enhanced H2O2  production 
via PBK-dependent stimulation of NADPH oxidase.123 Several laboratories have 
identified redox-sensitive intracellular signaling components which are known to be 
involved in cellular growth. HiOi-activated Src has been shown to transactivate growth 
factor receptors such as the epidermal growth factor receptor.110 Other potentially
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important downstream effectors of Src are ERK1/2 and p90 ribosomal S6 kinase 
(p90RSK), which play an important role in cell growth by activating translational 
machinery and stimulating protein synthesis. Abe et al found that Fyn (Src family 
member) was essential for H2O2 stimulated ERK1/2 and p90RSK activity, and suggested 
a redox-sensitive mechanism of Ras and p90RSK regulation.109 Rao et al found that 
ERK 1/2, JNK and p38 may also be redox-sensitive and contribute to AP-l mediated 
transcription.124 Data gathered by Jin et al show that H2 O2  increases egr-1, fra-1, and c- 
jun mRNA levels in vascular smooth muscle cells in a tyrosine kinase dependent
125manner/
Collectively, these findings may offer another piece of the puzzle linking PDGF- 
AA with vascular remodeling in hypertension. The present study has demonstrated a 
crucial role for PDGF-AA in hypertensive ECM modification, and has not ruled out the 
possibility that PDGF-AA contributes to hypertrophic remodeling. Therefore, we believe 
that PDGF is one of many messengers in a complex integrated signaling network 
triggered by mechanical stress to promote vascular remodeling.




Elevated blood pressure is associated with varying degrees o f arterial growth and 
remodeling. We believe that the critical factor regulating vascular remodeling in 
hypertension is circumferential wall stress, which is transmitted through the ECM to all 
cells within the vessel wall. However, the mechanisms by which extracellular 
mechanical stress is sensed and converted into intracellular alterations in signal 
transduction and gene expression have yet to be fully elucidated. In the cell where the 
goal is to maintain equilibrium, and the balance between phosphorylation and 
dephosphorylation o f signaling molecules determines cellular outcome, what ultimately 
shifts the cell into a growth phase and triggers ECM production? Numerous studies have 
been performed to evaluate the various signaling pathways associated with the cellular 
response to external stimuli. In the acute phase of hypertension, we have recently 
demonstrated that cytosolic Src tyrosine kinases are required for ERK-MAPKinase- 
mediated c-fos expression in pressure-stimulated rat small mesenteric arteries.33 
However, the source of their activation was largely unknown. Cellular components at or 
near the cell surface were the next targets of our investigation. Our attention was 
immediately drawn to the integrin receptors which link the ECM to the cytoskeleton, 
although some investigators also suggested involvement o f mechanically-sensitive 
growth factor receptors.77 We also believed that growth factors and/or their receptors 
were probably involved in long-term process of vascular remodeling. This was supported 
by Dobrian et al in our laboratory who found increased expression o f PDGF-A mRNA
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and protein within the vascular wall in 1KIC hypertensive rats. Therefore, the goal of 
our continued endeavors has been to further characterize the mechanisms by which 
VSMCs sense changes in wall stress, transmit this information to the nucleus, and 
orchestrate long-term modifications at the tissue level. More specifically, the focus of the 
current studies was to determine the role of focal adhesion kinase (FAK), Src, and the 
PDGF receptor in the initiation and long-term propagation o f these cellular events 
towards vascular remodeling.
We chose to investigate Src and FAK because of their known association with 
integrin and growth factor receptor tyrosine kinase (RTK) signaling. Within the Src 
molecule, tyrosine 418 has been identified as the primary site o f autophosphorylation and 
tyrosine 215 is known to be phosphorylated following recruitment to an activated PDGF 
receptor. FAK also associates with integrins, focal adhesion complexes, and growth 
factor receptors. Upon phosphorylation, FAK provides a substrate for association with 
and activation o f other cytosolic proteins, including Src. FAK-Y397 is the major site of 
FAK autophosphorylation and serves as docking site for the Src homology (SH2/SH3) 
domain o f Src. Therefore, FAK was considered as a potential candidate for initiation of 
the phosphoregulatory cascade. However, Src originating from other activated receptors 
may have the ability to migrate and stimulate other pathways via SH2/SH3 binding 
domains.
For the acute studies, we pressurized pairs o f mesenteric arteries in a dual vessel 
apparatus which permitted both an experimental hypertensive (140 mmHg) vessel and a 
normotensive (90 mmHg) control vessel for each experiment. Based on previous data 
which demonstrated peak ERK 1/2 activation at 5 minutes o f  pressure stimulus, we
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examined the phosphorylated state o f Src and FAK at 1, 3, and 5 minutes. Results 
indicated that Src-Y418 is immediately activated within the first minute of pressure, 
whereas FAK-Y397 phosphorylation did not appear until 3 minutes o f hypertension. In 
order to further characterize the relationship between Src and FAK, the experiments were 
repeated using the Src-selective kinase inhibitor, PP1. We found that in the absence of 
Src kinase activity, FAK phosphorylation does not occur. Thus, we have identified a 
time course in the signaling cascade in which Src-pY418 mediates the downstream 
activation of FAK-Y397 and ERK 1/2, although the involvement o f other messengers in 
this sequence and absolute relationship between them remains unclear. The PDGF 
receptor does not appear to be involved in the acute setting, as evidenced by the lack of 
Src-Y215 activation. This was further confirmed by repeating the experiments in the 
presence of AG 1296, a selective kinase inhibitor o f the PDGF receptor. Results 
indicated that ERK 1/2 activation at 5 minutes o f pressure was unaffected by PDGF-R 
inhibition.
The next phase was designed to further evaluate the potential role of PDGF-AA in 
long-term vascular remodeling. The first part o f this phase included the perivascular 
carotid infusion o f PDGF-AA in normotensive rats. Results indicated that PDGF-AA is 
capable o f inducing outward hypertrophy in a similar manner to that which is seen in 
hypertension. The next step involved characterizing the effect o f CGP 53716, a selective 
PDGF receptor kinase inhibitor, on chronic arterial remodeling. We found that the 
presence o f CGP 53716 had no effect on VSMC hypertrophy, although there was a 
significant reduction in both total collagen content and collagen I mRNA expression 
within the aortic wall. We conclude ;*p+2Xthat PDGF is a critical mediator o f ECM component
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
75
production during the remodeling phase of hypertension and we cannot rule out the 
possible contribution to VSMC hypertrophy.
Overall, the present study has provided some key insight into hypertension as 
seen from the cell’s perspective. In such a complex dynamic system we have identified 
some of the key players in both the acute and chronic phases o f hypertension. In the 
initial phase the remaining question is what activates Src? Banes et al suggest that Src 
itself is mechanically sensitive and is part o f a mechanosensory complex linking integrins 
to the cytoskeleton,111 while others have implicated oxidative stress as the culprit.46 With 
regard to the chronic state, several investigators have suggested that remodeling is 
collaborative effort between several growth factors including PDGF, EGF, FGF, and 
TGF-p.96,121’122 These unanswered questions will be the focus o f fixture investigations.
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